Skip to main content
SpringerLink
Log in

Milnacipran

In Fibromyalgia

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Milnacipran is an orally administered selective serotonin and norepinephrine (noradrenaline) reuptake inhibitor indicated for the management of fibromyalgia in adults.

In adults, milnacipran was generally effective in the treatment of fibromyalgia in four well designed trials of 3 or 6 months’ duration. Composite responder rates for the treatment of fibromyalgia and fibromyalgia pain (co-primary efficacy variables) were generally higher with milnacipran 100 or 200 mg/day (in two divided doses) than with placebo after 12 weeks of fixed-dose treatment.

In one study, the composite responder rate for fibromyalgia pain (co-primary efficacy variable) was also higher with milnacipran 200 mg/day than with placebo after 24 weeks of fixed-dose treatment.

Furthermore, the benefits of milnacipran therapy were sustained in a 6-month extension of an initial double-blind trial. Improvements from baseline in mean 24-hour recall pain scores, mean weekly recall pain scores, Patient Global Impression of Change scores and in several items of the Fibromyalgia Impact Questionnaire were observed in patients receiving continuous milnacipran for up to 12 months, as well as in patients who switched from placebo to milnacipran therapy at the start of the extension phase.

Milnacipran was generally well tolerated in adults with fibromyalgia, with most adverse events being mild to moderate in severity. Nausea was the most common adverse event reported in milnacipran recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American College of Rheumatology. Fibromyalgia (fact sheet) [online]. Available from URL: http://www.rheumatology.org/public/factsheets/diseases_and_conditions/fibromyalgia.pdf [Accessed 2009 Jul 29]

  2. Spaeth M, Briley M. Fibromyalgia: a complex syndrome requiring a multidisciplinary approach. Hum Psychopharmacol Clin Exp 2009; 24 Suppl.: S3–10

    Article  Google Scholar 

  3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33(2): 160–72

    Article  PubMed  CAS  Google Scholar 

  4. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum 2006; 54(1): 169–76

    Article  PubMed  Google Scholar 

  5. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsych Dis Treat 2008; 4(6): 1059–71

    Article  CAS  Google Scholar 

  6. Stahl SM. Fibromyalgia: pathways and neurotransmitters. Hum Psychopharmacol Clin Exp 2009; 24 Suppl.: S1 1–7

    Google Scholar 

  7. Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. [online]. Available from URL: http://www.guideline.gov/summary/summary.aspx?ss=15doc_id=7298nbr=4342 [Accessed 2009 Jul 29]

  8. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs 2008; 68(15): 2205–23

    Article  PubMed  CAS  Google Scholar 

  9. Curran MP. Duloxetine: in patients with fibromyalgia. Drugs 2009; 69(9): 1217–27

    Article  PubMed  CAS  Google Scholar 

  10. Forest Pharmaceuticals Inc. Savella® (milnacipran HCl) tablets: US prescribing information [online]. Available from URL: http://www.frx.com/pi/Savella_pi.pdf [Accessed 2009 Jun 22]

  11. Spencer CM, Wilde MI. Milnacipran: a review of its use in depression. Drugs 1998 Sep; 56(3): 405–27

    Article  PubMed  CAS  Google Scholar 

  12. Moret C, Charveron M, Finberg JP, et al. Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985; 24(12): 1211–9

    Article  PubMed  CAS  Google Scholar 

  13. Hindmarch I, Rigney U, Stanley N, et al. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000 Feb; 49: 118–25

    Article  PubMed  CAS  Google Scholar 

  14. Poirier MF, Galinowski A, Amado I, et al. Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol Clin Exp 2004; 19: 1–7

    Article  CAS  Google Scholar 

  15. Caron J, Libersa C, Hazard JR, et al. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 1993 Dec; 3: 493–500

    Article  PubMed  CAS  Google Scholar 

  16. Ingvar M, Petzke F, Marcus H, et al. Precuneus contrast distinguishes milnacipran from placebo: an fMRI study in fibromyalgia patients [abstract no. 857.19/HH2]. Presented at the 38th Annual Meeting for the Society for Neuroscience; 2008 Nov 15–19; Washington, DC

  17. Pae C-U, Marks DM, Shah M, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009; 32(6): 355–63

    Article  Google Scholar 

  18. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol Clin Exp 2009; 24 Suppl.: S19–23

    Article  Google Scholar 

  19. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp 2004; 19 Suppl.: S15–9

    Article  CAS  Google Scholar 

  20. Arnold LM, Palmer RH, Hufford MR, et al. Milnacipran’s effect on body weight by baseline BMI: results across 3 randomized, double-blind, placebo-controlled fibromyalgia trials. Presented at the 73rd Annual American College of Rheumatology Meeting; 2009 Oct 17–21; Philadelphia (PA)

  21. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009 Feb; 36(2): 398–409

    Article  PubMed  CAS  Google Scholar 

  22. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008 Nov; 30(11): 1988–2004

    Article  PubMed  CAS  Google Scholar 

  23. Arnold LM, Gendreau RM, Spera A, et al. Milnacipran 100 mg/day in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Poster presented at the 73rd Annual Scientific American College of Rheumatology Meeting; 2009 Oct 16–21; Philadelphia (PA)

  24. Paris BL, Ogilvie BW, Scheinkienig JA, et al. In vitro inhibition and induction of human liver cytochrome P450 enzymes by milnacipran. Drug Metab Disp 2009; 37(10): 2045–54

    Article  CAS  Google Scholar 

  25. Puozzo C, Rostin M, Montastruc JL, et al. Absolute bioavailability study of midalcipran (F 2207) in volunteers. In: Third European Congress of Biopharmaceutics and Pharmacokinetics Proceedings; 1987 Apr 21–24; Freiburg, Switzerland, 59-68

  26. Puozzo C, Filaquier C, Briley M. Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers. Br J Clin Pharmacol 1985; 20: 291P

    Google Scholar 

  27. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996 Sep; 11 (Suppl. 4): 15-27

    Google Scholar 

  28. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005; 44(9): 977–88

    Article  PubMed  CAS  Google Scholar 

  29. Branco J, Bragee G, Zachrisson O, et al. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, double-blind, placebo-controlled trial [abstract no. P.8.a.014]. Eur Neuropsychopharmacol 2008 Aug; 18 Suppl. 4: S574–5

    Article  Google Scholar 

  30. Pierre Fabre Medicament. A multicentre trial to determine the efficacy and safety of milnacipran in the treatment of fibromyalgia syndrome [ClinicalTrials.gov identifier NCT00436033]. US National Institutes of Health, Clinical Trials.gov [online]. Availavle from URL: http://www.clinicaltrials.gov

  31. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004 Oct; 19 Suppl. 1: S27–35

    Article  PubMed  CAS  Google Scholar 

  32. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005 Oct; 32(10): 1975–85

    PubMed  CAS  Google Scholar 

  33. Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Int J Psych Clin Pract 2004; 8(1): 47–51

    Article  CAS  Google Scholar 

  34. Bennett R. The fibromyalgia impact questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23 Suppl. 39: S154–62

    PubMed  CAS  Google Scholar 

  35. Mease P, Palmer RH, Rao S, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from a dose-controlled, extension study [abstract no. 583]. Arthritis Rheum 2008; 58 (9 Suppl.): S383

    Google Scholar 

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: F. Blotman, Rheumatology Department, University Hospital of Montpellier, Montpellier, France; S. Carville, UK Age Research Forum, London, England; E. Diri, University of North Dakota, Minot, North Dakota, USA; I. Hindmarch, St. Margaret’s-at-Cliffe, Dover, Kent, England; G. McCleane, Rampark Pain Centre, Rampark, Lurgan, Ireland.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Claudine M. Chwieduk & Paul L. McCormack

Authors
  1. Claudine M. Chwieduk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudine M. Chwieduk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chwieduk, C.M., McCormack, P.L. Milnacipran. Drugs 70, 99–108 (2010). https://doi.org/10.2165/11202810-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11202810-000000000-00000

Keywords

Search

Navigation